Wnt5a在肿瘤进展中的作用具有争议性

doi:10.24920/003659

摘要/Abstract

摘要：

Wnt5a是Wnt家族中一种具有代表性的分子,它通过Wnt非经典途径调控多种细胞功能。虽然Wnt5a在多种病理状态中均有涉及,但其在肿瘤中的作用尚不明确。Wnt5a在肿瘤的作用机制中可能涉及甲基化修饰、不同的mRNA亚型以及调控不同的下游通路。因此,Wnt5a在肿瘤发展起重要作用（侵袭、迁移、增殖、以及上皮-间质转化）,是一个潜在的预后和治疗的生物标志物。

关键词: Wnt5a, 肿瘤, 甲基化修饰

Abstract:

Wnt5a is a representative Wnt ligand that regulates multiple cellular functions through the Wnt5a non-classical pathway. Although Wnt5a has been implicated in various pathological conditions, its role in cancer is ambiguous and might involve methyl modifications, distinct mRNA isoforms, as well as different downstream pathways. Therefore, it is an essential factor in cancers’ progression (invasion, migration, proliferation, and epithelial-mesenchymal transition), and a potential biomarker for prognosis and treatment.

Key words: Wnt5a, cancer, methyl modification

补充说明: 甘肃省卫生行业科研计划项目基金（项目编号：GSWSKY2018-34）

基金资助: 甘肃省卫生行业科研计划项目基金(GSWSKY2018-34)

Xu Chen, Hongling Liu, Fenghui Zhao, Zongxian Jiao, Jinsui Wang, Yamei Dang. Wnt5a Plays Controversial Roles in Cancer Progression[J].Chinese Medical Sciences Journal, 2020, 35(4): 357-365.

图/表 3

参考文献 91.

1.	Wang X, Zhao X, Yi Z, et al. WNT5A promotes migration and invasion of human osteosarcoma cells via SRC/ERK/MMP-14 pathway. Cell Bio Int 2018; 42(5):598-607. doi: 10.1002/cbin.10936. doi: 10.1002/cbin.v42.5
2.	Wang W, Yu X, Wu C, et al. Differential effects of Wnt5a on the proliferation, differentiation and inflammatory response of keratinocytes. Mol Med Rep 2017; 17(3):4043-48. doi: 10.3892/mmr.2017.8358. doi: 10.3892/mmr.2017.8358 pmid: 29286164
3.	Feng C, Liang S, Harold V. Wnt signals across the plasma membrane to activate the beta-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP. Development 2004; 131:5103-15. doi: 10.1089/scd.2015.0367. doi: 10.1242/dev.01318 pmid: 15459103
4.	Zins K, Schäfer R, Paulus P, et al. Frizzled2 signaling regulates growth of high-risk neuroblastomas by interfering with β-catenin-dependent and β-catenin-independent signaling pathways. Oncotarget 2016; 7(29):46187-202. doi: 10.18632/oncotarget.10070. pmid: 27323822
5.	Keller KC, Ding H, Tieu R, et al. Wnt5a Supports Osteogenic Lineage Decisions in Embryonic Stem Cells. Stem Cells Dev 2016; 25(13):1020-32. doi: 10.1089/scd.2015.0367. pmid: 26956615
6.	Abedini A, Zamberlam G, Lapointe E, et al. WNT5a is required for normal ovarian follicle development and antagonizes gonadotropin responsiveness in granulosa cells by suppressing canonical WNT signaling. Faseb J 2016; 30(4):1534-47. doi: 10.1096/fj.15-280313. doi: 10.1096/fj.15-280313 pmid: 26667040
7.	Saling M, Duckett JK, Ackers I, et al. Wnt5a/planar cell polarity signaling pathway in urothelial carcinoma, a potential prognostic biomarker. Oncotarget 2017; 8(19):31655-65. doi: 10.18632/oncotarget.15877. doi: 10.18632/oncotarget.15877 pmid: 28427201
8.	Zhong Z, Shan M, Wang J, et al. Decreased Wnt5a Expression is a Poor Prognostic Factor in Triple-Negative Breast Cancer. Med Sci Monit 2016; 22:1-7. doi: 10.12659/MSM.894821 pmid: 26721633
9.	Matthieu B, Jean B, Terry G, et al. WNT5A encodes two isoforms with distinct functions in cancers. Plos One 2013; 8:e80526. doi: 10.1371/journal.pone.0080526. doi: 10.1371/journal.pone.0080526 pmid: 24260410
10.	Gavin BJ, Mcmahon JA, Mcmahon AP. Expression of multiple novel Wnt-1/int-1-related genes during fetal and adult mouse development. Genes Dev 1990; 4(12B):2319-32. doi: 10.1101/gad.4.12b.2319. pmid: 2279700
11.	Parr BA, Mcmahon AP. Wnt genes and vertebrate development. Cur Opinion Genet Develop 1994; 4(4):523-8. doi: 10.1016/0959-437X(94)90067-D.
12.	Clark CC, Cohen I, Eichstetter I, et al. Molecular cloning of the human proto-oncogene Wnt-5A and mapping of the gene (WNT5A) to chromosome 3p14-p21. Genomics 1993; 18(2):249-60. doi: 10.1006/geno.1993.1463. doi: 10.1006/geno.1993.1463 pmid: 8288227
13.	Lin HK, Lin HH, Chiou YW, et al. Caveolin-1 down-regulation is required for Wnt5a-Frizzled 2 signalling in Ha-RasV12-induced cell transformation. J Cellular Molecular Med 2018; 22(5):2631-43. doi: 10.1111/jcmm.13531. doi: 10.1111/jcmm.2018.22.issue-5
14.	Wang HY, Liu T, Malbon CC. Structure-function analysis of Frizzleds. Cell Signal 2006; 18(7):934-41. doi: 10.1016/j.cellsig.2005.12.008. doi: 10.1016/j.cellsig.2005.12.008
15.	Bischoff DS, Zhu JH, Makhijani NS, et al. Induction of CXC chemokines in human mesenchymal stem cells by stimulation with secreted frizzled-related proteins through non-canonical Wnt signaling. World J Stem Cells 2015; 7(11):1262-73. doi: 10.4252/wjsc.v7.i11.1262. doi: 10.4252/wjsc.v7.i11.1262 pmid: 26730270
16.	Uehara S, Udagawa N, Mukai H, et al. Protein kinase N3 promotes bone resorption by osteoclasts in response to Wnt5a-Ror2 signaling. Sci Signaling 2017; 10(494):e0023. doi: 10.1126/scisignal.aan0023.
17.	Skaria T, Bachli E, Schoedon G. Wnt5A/Ryk signaling critically affects barrier function in human vascular endothelial cells. Cell Adh Migr 2016; 11(1):24-38. doi: 10.1080/19336918.2016.1178449. pmid: 27159116
18.	Adamo A, Fiore D, Martino FD, et al. RYK promotes the stemness of glioblastoma cells via the WNT/ β-catenin pathway. Oncotarget 2017; 8(26):13476-87. doi: 10.18632/oncotarget.14564. doi: 10.18632/oncotarget.v8i8
19.	Sakisaka Y, Kanaya S, Nakamura T, et al. p38 MAP kinase is required for Wnt3a-mediated osterix expression independently of Wnt-LRP5/6-GSK3β signaling axis in dental follicle cells. Biochem Biophys Res Commun 2016; 478(2):527-32. doi: 10.1016/j.bbrc.2016.07.076. doi: 10.1016/j.bbrc.2016.07.076 pmid: 27450807
20.	Lai K, Kweon SM, Chi F, et al. Abstract 4331: Novel Wnt-SCD-LRP5/6 pathway linking liver fibrosis to cancer. Cancer Res 2017; 77. doi: 10.1158/1538-7445.AM2017-4331. doi: 10.1158/0008-5472.CAN-17-2066 pmid: 29097609
21.	Kim JG, Kim MJ, Choi WJ, et al. Wnt3A Induces GSK-3β Phosphorylation and β-Catenin Accumulation Through RhoA/ROCK. J cell physiol 2017; 232(5). 1104-13. doi: 10.1002/jcp.25572. doi: 10.1002/jcp.25572 pmid: 27575935
22.	Daniels DL, Weis WI. β-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 2005; 12(4):364-71. doi: 10.1038/nsmb912. pmid: 15768032
23.	Yu L, Liu S, Zhao Z, et al. Extracorporeal shock wave rebuilt subchondral bone in vivo and activated Wnt5a/Ca²+ signaling in vitro. Biomed Res Int 2017; 2017:1404650. doi: 10.1155/2017/1404650. doi: 10.1155/2017/1404650 pmid: 29164146
24.	Hatziapostolou M, Koukos G, Polytarchou C, et al. Tumor progression locus 2 mediates signal-induced increases in cytoplasmic calcium and cell migration. Sci Signal 2011; 4(187):e55. doi: 10.1126/scisignal.2002006.
25.	Ho HYH, Susman MW, Bikoff JB, et al. Wnt5a-Ror-Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis. Proc Natl Acad Sci U S A 2012; 109(1):4044-51. doi: 10.1073/pnas.1200421109. doi: 10.1073/pnas.1200421109
26.	Martineau X, Abed É, Martel-Pelletier J, et al. Alteration of Wnt5a expression and of the non-canonical Wnt/PCP and Wnt/PKC-Ca²+ pathways in human osteoarthritis osteoblasts. Plos One 2017; 12(8):e0180711. doi: 10.1371/journal.pone.0180711. doi: 10.1371/journal.pone.0180711 pmid: 28777797
27.	Chen M, Zhong W, Hu Y, et al. Wnt5a/FZD5/CaMKII signaling pathway mediates the effect of BML-111 on inflammatory reactions in sepsis. Int J Clin Exp Med 2015; 8(10):17824-9. pmid: 26770375
28.	Chattopadhyay S, Chatterjee R, Law S. Noncanonical Wnt5a-Ca²+-NFAT signaling axis in pesticide induced bone marrow aplasia mouse model: A study to explore the novel mechanism of pesticide toxicity. Environ Toxicol 2016(10); 31:1163-75. doi: 10.1002/tox.22123. doi: 10.1002/tox.22123 pmid: 25846497
29.	Saling M, Duckett JK, Ackers I, et al. Wnt5a/planar cell polarity signaling pathway in urothelial carcinoma, a potential prognostic biomarker. Oncotarget 2017; 8(19):31655-65. doi: 10.18632/oncotarget.15877. doi: 10.18632/oncotarget.15877 pmid: 28427201
30.	Hasegawa D, Wada N, Yoshida S, et al. Wnt5a suppresses osteoblastic differentiation of human periodontal ligament stem cell-like cells via Ror2/JNK signaling. J cell physiol 2018; 233(2):1752-62. doi: 10.1002/jcp.26086. doi: 10.1002/jcp.26086 pmid: 28681925
31.	Yu J, Chen Y, Chen L, et al. Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget 2018; 9(37):24731-6. doi: 10.18632/oncotarget.25340. doi: 10.18632/oncotarget.25340 pmid: 29872501
32.	Yu J, Chen L, Chen Y, et al. Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia 2017; 31(12):2608-14. doi: 10.1038/leu.2017.132. doi: 10.1038/leu.2017.132 pmid: 28465528
33.	Prasad CP, Södergren K, Andersson T. Reduced production and uptake of lactate are essential for the ability of WNT5A signaling to inhibit breast cancer cell migration and invasion. Oncotarget 2017; 8(42):71471-88. doi: 10.18632/oncotarget.17277. pmid: 29069720
34.	Li J, Ying J, Fan Y, et al. WNT5A antagonizes WNT/β-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. Cancer Biol Ther 2010; 10(6):617-24. doi: 10.4161/cbt.10.6.12609. doi: 10.4161/cbt.10.6.12609 pmid: 20603606
35.	Ann EJ, Kim HY, Seo MS, et al. Wnt5a controls Notch1 signaling through CaMKII-mediated degradation of the SMRT corepressor protein. J Biol Chem 2012; 287(44):36814-29. doi: 10.1074/jbc.M112.356048. doi: 10.1074/jbc.M112.356048 pmid: 22888005
36.	R John M, Madeline H. Wnt5a secretion stimulated by the extracellular calcium-sensing receptor inhibits defective Wnt signaling in colon cancer cells. Am J Physiol Gastrointest Liver Physiol 2007; 293(1):G403-11. doi: 10.1152/ajpgi.00119.2007. doi: 10.1152/ajpgi.00119.2007 pmid: 17463182
37.	Voloshanenko O, Schwartz U, Kranz D, et al. β-catenin-independent regulation of Wnt target genes by RoR2 and ATF2/ATF4 in colon cancer cells. Sci Rep 2018; 8(1):3178. doi: 10.1038/s41598-018-20641-5. pmid: 29453334
38.	Bergenfelz C, Medrek C, Ekström E, et al. Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients. J Immunol 2012; 188(11):5448-58. doi: 10.4049/jimmunol.1103378. doi: 10.4049/jimmunol.1103378 pmid: 22547701
39.	Zhang W, Yan Y, Gu M, et al. High expression levels of Wnt5a and Ror2 in laryngeal squamous cell carcinoma are associated with poor prognosis. Oncol letters 2017; 14(2):2232-8. doi: 10.3892/ol.2017.6386. doi: 10.3892/ol.2017.6386
40.	Dai B, Yan T, Zhang A. ROR2 receptor promotes the migration of osteosarcoma cells in response to Wnt5a. Cancer Cell Int 2017; 17:112. doi: 10.1186/s12935-017-0482-y. doi: 10.1186/s12935-017-0482-y pmid: 29213214
41.	Oishi I, Suzuki H, Onishi N, et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signaling pathway. Genes Cells 2003; 8(7):645-54. doi: 10.1046/j.1365-2443.2003.00662.x. doi: 10.1046/j.1365-2443.2003.00662.x pmid: 12839624
42.	Nam S, Chung JW, Yang JY. WNT5A correlates with clinicopathological characteristics in gastric cancer: a meta-analysis. Cell Physiol Biochem 2017; 41(1):33-40. doi: 10.1159/000455934. doi: 10.1159/000455934 pmid: 28135710
43.	Ara H, Takagishi M, Enomoto A, et al. Role for Daple in non-canonical Wnt signaling during gastric cancer invasion and metastasis. Cancer Sci 2016; 107(2):133-9. doi: 10.1111/cas.12848. doi: 10.1111/cas.12848 pmid: 26577606
44.	Liu J, Zhang Y, Xu R, et al. PI3K/Akt-dependent phosphorylation of GSK3β and activation of RhoA regulate Wnt5a-induced gastric cancer cell migration. Cell Signal 2013; 25(2):447-56. doi: 10.1016/j.cellsig.2012.10.012. doi: 10.1016/j.cellsig.2012.10.012 pmid: 23123500
45.	Hanaki H, Yamamoto H, Sakane H, et al. An anti-Wnt5a antibody suppresses metastasis of gastric cancer cells in vivo by inhibiting receptor-mediated endocytosis. Mol Cancer Ther 2012; 11(2):298-307. doi: 10.1158/1535-7163.mct-11-0682. doi: 10.1158/1535-7163.MCT-11-0682 pmid: 22101459
46.	Yamamoto H, Kitadai Y, Naohide Oue, et al. Laminin γ2 Mediates Wnt5a-Induced Invasion of Gastric Cancer Cells. Gastroenterology 2009; 137(1):242-52. doi: 10.1053/j.gastro.2009.02.003. doi: 10.1053/j.gastro.2009.02.003
47.	Kanzawa M, Semba S, Hara S, et al. WNT5A is a key regulator of the epithelial-mesenchymal transition and cancer stem cell properties in human gastric carcinoma cells. Pathobiology 2013; 80(5):235-44. doi: 10.1159/000346843. doi: 10.1159/000346843 pmid: 23615002
48.	Zhang Y, Du J, Zheng J, et al. EGF-reduced Wnt5a transcription induces epithelial-mesenchymal transition via Arf6-ERK signaling in gastric cancer cells. Oncotarget 2015; 6:7244-61. doi: 10.18632/oncotarget.3133. doi: 10.18632/oncotarget.3133 pmid: 25779663
49.	Takiguchi G, Nishita M, Kurita K, et al. Wnt5a-Ror2 signaling in mesenchymal stem cells promotes proliferation of gastric cancer cells by activating CXCL16-CXCR6 axis. Cancer Sci 2016; 107(9):290-7. doi: 10.1111/cas.12871. doi: 10.1111/cas.2016.107.issue-3
50.	Dejmek J, Dejmek A, Säfholm A, et al. Wnt-5a protein expression in primary Dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res 2005; 65:9142-6. doi: 10.1158/0008-5472.CAN-05-1710. doi: 10.1158/0008-5472.CAN-05-1710 pmid: 16230369
51.	Tao J, Shi L, Huang L, et al. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line. J Cancer Res Clin Oncol 2017; 143(11):2211-9. doi: 10.1007/s00432-017-2479-2. doi: 10.1007/s00432-017-2479-2 pmid: 28748258
52.	Mehdawi LM, Prasad CP, Ehrnström R, et al. Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells. Mol Oncol 2016; 10:1415-29. doi: 10.1016/j.molonc.2016.07.011. doi: 10.1016/j.molonc.2016.07.011 pmid: 27522468
53.	Cheng R, Sun B, Liu Z, et al. Wnt5a suppresses colon cancer by inhibiting cell proliferation and epithelial-mesenchymal transition. J Cell Physiol 2014; 229(12):1908-17. doi: 10.1002/jcp.24566. doi: 10.1002/jcp.24566 pmid: 24464650
54.	Wang J, Wang X, Liu F, et al. microRNA-335 inhibits colorectal cancer HCT116 cells growth and epithelial-mesenchymal transition (EMT) process by targeting Twist1. Pharmazie 2017; 72(8):475-81. doi: 10.1691/ph.2017.7489. doi: 10.1691/ph.2017.7489 pmid: 29441907
55.	Bakker ERM, Das AM, Helvensteijn W, et al. Wnt5a promotes human colon cancer cell migration and invasion but does not augment intestinal tumorigenesis in Apc 1638N mice. Carcinogenesis 2013; 34(11):2629-38. doi: 10.1093/carcin/bgt215. doi: 10.1093/carcin/bgt215 pmid: 23764752
56.	Huang TC, Lee PT, Wu MH, et al. Distinct roles and differential expression levels of Wnt5a mRNA isoforms in colorectal cancer cells. PloS One 2017; 12(8):e0181034. doi: 10.1371/journal.pone.0181034. doi: 10.1371/journal.pone.0181034 pmid: 28859077
57.	Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377(20):1919-29. doi: 10.1056 /nejmoa1709937. doi: 10.1056/NEJMoa1709937 pmid: 28885881
58.	Liu M, Zhang Y, Zhang J, et al. MicroRNA-1253 suppresses cell proliferation and invasion of non-small-cell lung carcinoma by targeting WNT5A. Cell Death Dis 2018; 9(2):189. doi: 10.1038/s41419-017-0218-x. doi: 10.1038/s41419-017-0218-x pmid: 29415994
59.	Wang B, Tang Z, Gong H, et al. Wnt5a promotes epithelial-to-mesenchymal transition and metastasis in non-small-cell lung cancer. Biosci Rep 2017; 37(6): BSR20171092. doi: 10.1042/BSR20171092. doi: 10.1042/BSR20171092 pmid: 29054966
60.	Huang Cl, Liu D, Nakano J, et al. Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor: An expression in non-small-cell lung cancer. J Clinc Oncol 2005; 23(34):8765-73. doi: 10.1200/jco.2005.02.2871.
61.	Whang YM, Jo U, Sung JS, et al. Wnt5a is associated with cigarette smoke-related lung carcinogenesis via protein kinase C. PLoS One 2013; 8(1):e53012. doi: 10.1371/journal.pone.0053012. doi: 10.1371/journal.pone.0053012 pmid: 23349696
62.	Yang J, Zhang K, Wu J, et al. Wnt5a increases properties of lung cancer stem cells and resistance to cisplatin through activation of Wnt5a/PKC signaling pathway. Stem Cells Int 2016; 2016:1690896. doi: 10.1155/2016/1690896. doi: 10.1155/2016/1690896 pmid: 27895670
63.	Kobayashi Y, Kadoya T, Amioka A, et al. Wnt5a-induced cell migration is associated with the aggressiveness of estrogen receptor-positive breast cancer. Oncotarget 2018; 9(30):20979-92. doi: 10.18632/oncotarget.24761. doi: 10.18632/oncotarget.24761 pmid: 29765514
64.	Prasad CP, Chaurasiya SK, Guilmain W, et al. WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition. J Exp Clin Cancer Res 2016; 35(1):144. doi: 10.1186/s13046-016-0421-0. doi: 10.1186/s13046-016-0421-0 pmid: 27623766
65.	Prasad CP, Chaurasiya SK, Axelsson L, et al. WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells. Mol Oncol 2013; 7(5):870-83. doi: 10.1016/j.molonc.2013.04.005. doi: 10.1016/j.molonc.2013.04.005 pmid: 23727359
66.	Chrysanthou E, Gorringe KL, Joseph C, et al. Phenotypic characterisation of breast cancer: the role of CDC42. Breast Cancer Res Treat 2017; 164(2):317-25. doi: 10.1007/s10549-017-4267-8. doi: 10.1007/s10549-017-4267-8 pmid: 28451966
67.	Jiang W, Crossman DK, Mitchell EH, et al. WNT5A inhibits metastasis and alters splicing of Cd44 in breast cancer cells. PLoS One 2013; 8(3):e58329. doi: 10.1371/journal.pone.0058329. doi: 10.1371/journal.pone.0058329 pmid: 23484019
68.	Han B, Zhou B, Qu Y, et al. FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer. Oncogene 2018; 37(10):1399-408. doi: 10.1038/s41388-017-0021-2. doi: 10.1038/s41388-017-0021-2 pmid: 29249801
69.	Zhu Y, Tian Y, Du J, et al. Dvl2-dependent activation of Daam1 and RhoA regulates Wnt5a-induced breast cancer cell migration. PLoS One 2012; 7(5):e37823. doi: 10.1371/journal.pone.0037823. doi: 10.1371/journal.pone.0037823 pmid: 22655072
70.	Zoico E, Darra E, Rizzatti V, et al. Adipocytes WNT5a mediated dedifferentiation: a possible target in pancreatic cancer microenvironment. Oncotarget 2016; 7(15):20223-35. doi: 10.18632/oncotarget.7936. doi: 10.18632/oncotarget.7936 pmid: 26958939
71.	Bo H, Gao L, Chen Y, et al. Upregulation of the expression of Wnt5a promotes the proliferation of pancreatic cancer cells in vitro and in a nude mouse model. Mol Med Rep 2016; 13(2):1163-71. doi: 10.3892/mmr.2015.4642. doi: 10.3892/mmr.2015.4642 pmid: 26648282
72.	Bo H, Zhang S, Gao L, et al. Upregulation of Wnt5a promotes epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells. BMC Cancer 2013; 13:496. doi: 10.1186/1471-2407-13-496. doi: 10.1186/1471-2407-13-496 pmid: 24156409
73.	Wei W, Li H, Li N, et al. WNT5A/JNK signaling regulates pancreatic cancer cells migration by phosphorylating paxillin. Pancreatology 2013; 13(4):384-92. doi: 10.1016/j.pan.2013.05.008. doi: 10.1016/j.pan.2013.05.008 pmid: 23890137
74.	Wei W, Sun HH, Li N, et al. WNT5A modulates cell cycle progression and contributes to the chemoresistance in pancreatic cancer cells. Hepatobiliary Pancreat Dis Int 2014; 13(5):529-38. doi: 10.1016/S1499-3872(14)60277-0. doi: 10.1016/s1499-3872(14)60277-0 pmid: 25308364
75.	Yamamoto H, Oue N, Sato A, et al. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 2010; 29(14):2036-46. doi: 10.1038/onc.2009.496. doi: 10.1038/onc.2009.496 pmid: 20101234
76.	Thiele S, Zimmer A, Göbel A, et al. Role of WNT5A receptors FZD5 and RYK in prostate cancer cells. Oncotarget 2018; 9(43):27293-304. doi: 10.18632/oncotarget.25551. doi: 10.18632/oncotarget.25551 pmid: 29930766
77.	Lee GT, Kang DI, Ha YS, et al. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction. Br J Cancer 2014; 110:1634-44. doi: 10.1038/bjc.2014.23. doi: 10.1038/bjc.2014.23 pmid: 24518599
78.	Lee GT, Kwon SJ, Kim J, et al. WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages. Br J Cancer 2018; 118(5):670-8. doi: 10.1038/bjc.2017.451. doi: 10.1038/bjc.2017.451 pmid: 29381686
79.	Jin F, Qu X, Fan Q, et al. Regulation of prostate cancer cell migration toward bone marrow stromal cell-conditioned medium by Wnt5a signaling. Mol Med Rep 2013; 8(5):1486-92. doi: 10.3892/mmr.2013.1698. doi: 10.3892/mmr.2013.1698 pmid: 24064566
80.	Thiele S, Göbel A, Rachner TD, et al. WNT5A has anti-prostate cancer effects in vitro and reduces tumor growth in the skeleton in vivo. J Bone Miner Res 2015; 30(3):471-80. doi: 10.1002/jbmr.2362. doi: 10.1002/jbmr.2362 pmid: 25224731
81.	Canesin G, Evans-Axelsson S, Hellsten R, et al. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One 2017; 12(9):e0184418. doi: 10.1371/journal.pone.0184418. doi: 10.1371/journal.pone.0184418 pmid: 28886116
82.	Ndoye A, Budina A, Webster M, et al. Role of autophagy in Wnt5A-mediated melanoma invasion and metastasis. Cancer Res 2015; 75(15):2906. doi: 10.1158/1538-7445.AM2015-2906.
83.	Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002; 1(3):279-88. doi: 10.1016/S1535-6108(02)00045-4. doi: 10.1016/s1535-6108(02)00045-4 pmid: 12086864
84.	Ekström EJ, Bergenfelz C, von Bülow V, et al. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol Cancer 2014; 13:88. doi: 10.1186/1476-4598-13-88. doi: 10.1186/1476-4598-13-88 pmid: 24766647
85.	Anastas JN, Kulikauskas RM, Tamir T, et al. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Invest 2014; 124(7):2877-90. doi: 10.1172/JCI70156. doi: 10.1172/JCI70156 pmid: 24865425
86.	Ying J, Li H, Chen YW, et al. WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor. Blood 2007; 110(12):4130-1. doi: 10.1182/blood-2007-06-094870. doi: 10.1182/blood-2007-06-094870 pmid: 18024799
87.	Hasan MK, Yu J, Chen L, et al. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. Leukemia 2017; 31(12):2615-22. doi: 10.1038/leu.2017.133. pmid: 28465529
88.	Despeaux M, Chicanne G, Rouer E, et al. Focal adhesion kinase splice variants maintain primitive acute myeloid leukemia cells through altered Wnt signaling. Stem Cells 2012; 30(8):1597-610. doi: 10.1002/stem.1157. doi: 10.1002/stem.1157 pmid: 22714993
89.	Yu J, Chen L, Cui B, et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J Clin Invest 2016; 126(2):585-98. doi: 10.1172/JCI83535. doi: 10.1172/JCI83535 pmid: 26690702
90.	Ng ÖH, Fırtına S, Can İ, et al. A possible role for WNT5A hypermethylation in pediatric acute lymphoblastic leukemia. Turk J Haematol 2015; 32(2):127-35. doi: 10.4274/Tjh.2013.0296. doi: 10.4274/tjh.2013.0296 pmid: 26316480
91.	Zhou HR, Fu HY, Wu DS, et al. Relationship between epigenetic changes in Wnt antagonists and acute leukemia. Oncology Rep 2017; 37(5):2663-71. doi: 10.3892/or.2017.5509.

[1]	陈旭, 刘红玲, 李德红, 王金穗, 赵凤辉. Wnt5a在炎性疾病中具有双向调节性[J]. Chinese Medical Sciences Journal, 2022, 37(3): 265-274.
[2]	李铁力, 丁海璇, 赵新兰, 罗娟, 陈凯, 唐卓, 黄凌云, 李浪波, 杨丽. MODY₃合并肠道神经内分泌肿瘤：1例病例报道[J]. Chinese Medical Sciences Journal, 2022, 37(2): 167-170.
[3]	欧阳思文, 康维明. 角蛋白在胃肠道肿瘤中的作用和研究进展[J]. Chinese Medical Sciences Journal, 2022, 37(1): 73-78.
[4]	王亮, 李刚, 邴运韬, 田茂霖, 王行雁, 原春辉, 修典荣. 既往癌症对局限性胰腺神经内分泌肿瘤患者的生存结果有影响吗?[J]. Chinese Medical Sciences Journal, 2021, 36(4): 284-294.
[5]	田捷. 人工智能推进肿瘤精准诊疗迈向新台阶[J]. Chinese Medical Sciences Journal, 2021, 36(3): 171-172.
[6]	李刚, 邴运韬, 田茂霖, 原春辉, 修典荣. 使用列线图预测老年胰腺神经内分泌肿瘤患者手术前远处转移的风险[J]. Chinese Medical Sciences Journal, 2021, 36(3): 218-224.
[7]	李佳铮, 唐磊. 影像组学在抗肿瘤药物临床试验疗效评估中的应用和挑战[J]. Chinese Medical Sciences Journal, 2021, 36(3): 187-195.
[8]	吕杰,原杰,徐朝健,郝家齐,秦一川,王小强,王永峰. 骨肉瘤MG63细胞中VEGF-C/VEGFR-3/iNOS信号转导对人脐静脉内皮细胞增殖的促进作用[J]. Chinese Medical Sciences Journal, 2021, 36(1): 35-42.
[9]	刘炬,徐志坚,毕晓峰,孙萍,黄佳琴. 135个父母双亲和子女均患癌症的中国家庭发病特征回顾性分析[J]. Chinese Medical Sciences Journal, 2021, 36(1): 27-34.
[10]	曹艳杰,段景琪,刘丽芳,魏璇,任力,张蓝宁,张伟. 个体化及缓和医疗用于90岁胃原发弥漫性大B细胞淋巴瘤患者：4年随访结果及启示[J]. Chinese Medical Sciences Journal, 2021, 36(1): 72-77.
[11]	曹剑, 王国蓉, 王志伟, 金征宇. CT纹理分析：结直肠癌KRAS基因突变状态评估的潜在生物标志物[J]. Chinese Medical Sciences Journal, 2020, 35(4): 306-314.
[12]	黄超, 向科明, 梁炳君, 黄伟旋, 张樊君, 邵玉婉, 王秀莲, 刘浩生, 沈维增. 吴茱萸碱联合小檗碱对CCD-18Co诱导的结肠上皮细胞表型转化的调节效应[J]. Chinese Medical Sciences Journal, 2020, 35(3): 195-206.
[13]	王站, 王旭, 王文达, 郑国洋, 郭浩, 张玉石. 术前中性粒细胞与淋巴细胞比值预测可切除泌尿系肿瘤预后的价值：系统综述和荟萃分析[J]. Chinese Medical Sciences Journal, 2020, 35(3): 262-271.
[14]	张傲利,陈晓娟,李占奇,竺晓凡. 原始神经外胚层肿瘤作为长期存活的急性淋巴细胞白血病儿童的第二恶性肿瘤：病例报告[J]. Chinese Medical Sciences Journal, 2020, 35(2): 186-190.
[15]	朱海燕, 戴敏. 1例以腹股沟肿块为表现的胰腺癌[J]. Chinese Medical Sciences Journal, 2020, 35(1): 101-104.

优先出版

当期目次

过刊浏览

虚拟专题

作者中心

评阅者中心